Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02295475 · ClinicalTrials.gov registry record · Phase 4

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

A Phase 4 study of Thrombosis and Antiphospholipid Syndrome, sponsored by Scott C. Woller, MD.

Completed
Registry status
Phase 4
Development phase
48
Enrollment target
2
Study locations

NCT02295475 is a Phase 4 study of Thrombosis and Antiphospholipid Syndrome that has completed, run by Scott C. Woller, MD. The registered enrollment target is 48 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02295475, a Phase 4 study of Thrombosis and Antiphospholipid Syndrome, has completed, sponsored by Scott C. Woller, MD.

COMPLETED
Registry status
Phase 4
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

Conditions Studied

Thrombosis Antiphospholipid Syndrome

Interventions

  • DRUG Apixaban
  • DRUG Warfarin

Study Locations (2)

Ohio

  • The James Comprehensive Cancer Center - Columbus

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-12-10
Est. Completion 2022-03
Phase Phase 4

Sponsor

Scott C. Woller, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02295475

The ClinicalTrials.gov registry entry for NCT02295475 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (90% lower). The listed sponsor is Scott C. Woller, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.

NCT02295475 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Utah.

Frequently Asked Questions

What is clinical trial NCT02295475 about?

NCT02295475 is a clinical study titled "Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome". This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

What is the current status of trial NCT02295475?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2014-12-10. Estimated completion is 2022-03.

What conditions does trial NCT02295475 study?

This clinical trial studies the following conditions: Thrombosis, Antiphospholipid Syndrome.

What interventions are being tested in trial NCT02295475?

The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).

Who is sponsoring clinical trial NCT02295475?

This trial is sponsored by Scott C. Woller, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02295475 being conducted?

This trial has 2 study locations across Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thrombosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thrombosis

All registered trials for this condition

Antiphospholipid Syndrome

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.